YHB Investment Advisors Inc. Buys New Shares in Invesco Biotechnology & Genome ETF $PBE

YHB Investment Advisors Inc. purchased a new position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 22,296 shares of the company’s stock, valued at approximately $2,169,000.

Other hedge funds also recently made changes to their positions in the company. Compass Financial Management LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the 2nd quarter valued at $27,000. Fifth Third Bancorp acquired a new position in Invesco Biotechnology & Genome ETF in the first quarter valued at $30,000. Integrated Wealth Concepts LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the second quarter valued at about $84,000. Dynamic Advisor Solutions LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the second quarter valued at about $484,000. Finally, Kestra Advisory Services LLC increased its stake in Invesco Biotechnology & Genome ETF by 7.0% during the first quarter. Kestra Advisory Services LLC now owns 6,280 shares of the company’s stock worth $497,000 after acquiring an additional 411 shares during the last quarter.

Invesco Biotechnology & Genome ETF Trading Down 0.8%

Shares of Invesco Biotechnology & Genome ETF stock traded down $0.73 during trading hours on Thursday, reaching $94.10. The stock had a trading volume of 5,991 shares, compared to its average volume of 13,848. The firm has a 50 day simple moving average of $95.29 and a two-hundred day simple moving average of $87.91. The firm has a market capitalization of $411.22 million, a price-to-earnings ratio of 20.44 and a beta of 0.70. Invesco Biotechnology & Genome ETF has a 1 year low of $70.01 and a 1 year high of $98.82.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.